Evolus (EOLS) Share-based Compensation Growth (3y) (2020 - 2026)
Evolus (EOLS) Share-based Compensation Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 10.06% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 9.14% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 0.43% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -8.13% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -1.73% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | -8.04% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Evolus | 550.51 Mn | 505.34 Mn | 57.18 Mn | 10.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.46% |
| Mar 31, 2026 | 15.81% |
| Sep 30, 2025 | 42.02% |
| Jun 30, 2025 | 14.64% |
| Mar 31, 2025 | 26.06% |
| Dec 31, 2024 | -100.59% |
| Sep 30, 2024 | 28.23% |
| Jun 30, 2024 | 26.45% |
| Mar 31, 2024 | 47.27% |
| Dec 31, 2023 | -81.96% |
| Sep 30, 2023 | 15.90% |
| Jun 30, 2023 | 20.67% |
| Mar 31, 2023 | 7.82% |
| Sep 30, 2022 | -63.25% |
| Jun 30, 2022 | -4.55% |
| Mar 31, 2022 | 42.20% |
| Dec 31, 2021 | -27.57% |
| Sep 30, 2021 | 38.94% |
| Jun 30, 2021 | -7.63% |
| Dec 31, 2020 | 184.68% |